{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:57:13Z","timestamp":1790996233183,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.addr.2018.06.004","type":"journal-article","created":{"date-parts":[[2018,6,8]],"date-time":"2018-06-08T00:47:09Z","timestamp":1528418829000},"page":"87-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Repurposing of gamma interferon via inhalation delivery"],"prefix":"10.1016","volume":"133","author":[{"given":"Gerald C.","family":"Smaldone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2018.06.004_bb0005","doi-asserted-by":"crossref","first-page":"6556","DOI":"10.1021\/bi00442a005","article-title":"pH dependence of the reversible and irreversible thermal denaturation of gamma interferons","volume":"28","author":"Mulkerrin","year":"1989","journal-title":"Biochemistry"},{"key":"10.1016\/j.addr.2018.06.004_bb0010","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1385\/MB:28:3:241","article-title":"Appropriate glycosylation of recombinant proteins for human use: implications of choice of expression system","volume":"28","author":"Brooks","year":"2004","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.addr.2018.06.004_bb0015","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003495-199243010-00008","article-title":"Interferon gamma-1b. A review of its pharmacology and therapeutic potential in chronic granulomatous disease","volume":"43","author":"Todd","year":"1992","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2018.06.004_bb0020","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM199506153322402","article-title":"Long-term treatment of osteopetrosis with recombinant human interferon gamma","volume":"332","author":"Key","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2018.06.004_bb0025","unstructured":"Centers for Disease Control http:\/\/www.cdc.gov\/tb\/topic\/testing\/default.htm. retreived June 30, (2014)."},{"key":"10.1016\/j.addr.2018.06.004_bb0030","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/thx.2005.051649","article-title":"Disseminated Mycobacterium tuberculosis infection due to interferon gamma deficiency. Response to replacement therapy","volume":"62","author":"Seneviratne","year":"2007","journal-title":"Thorax"},{"key":"10.1016\/j.addr.2018.06.004_bb0035","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(04)17552-1","article-title":"Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies","volume":"364","author":"Dorman","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2018.06.004_bb0040","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1056\/NEJM199405123301904","article-title":"Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. A preliminary report","volume":"330","author":"Holland","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2018.06.004_bb0045","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1203\/00006450-200107000-00005","article-title":"Impaired interferon gamma-mediated immunity and susceptibility to mycobacterial infection in childhood","volume":"50","author":"Remus","year":"2001","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.addr.2018.06.004_bb0050","unstructured":"g.b. ACTIMMUNE Interferon, http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/103836s5098LBL.pdf."},{"key":"10.1016\/j.addr.2018.06.004_bb0055","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(96)12273-X","article-title":"Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol","volume":"349","author":"Condos","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2018.06.004_bb0060","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1089\/089426803772455631","article-title":"Lung deposition and respirable mass during wet nebulization","volume":"16","author":"Sangwan","year":"2003","journal-title":"J. Aerosol Med."},{"key":"10.1016\/j.addr.2018.06.004_bb0065","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1378\/chest.125.6.2146","article-title":"Regional deposition of aerosolized interferon-gamma in pulmonary tuberculosis","volume":"125","author":"Condos","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.addr.2018.06.004_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0006984","article-title":"Immunomodulation with recombinant interferon-gamma1b in pulmonary tuberculosis","volume":"4","author":"Dawson","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2018.06.004_bb0075","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0167-5699(97)01000-1","article-title":"Reciprocal IFN-gamma and TGF-beta responses regulate the occurrence of mucosal inflammation","volume":"18","author":"Strober","year":"1997","journal-title":"Immunol. Today"},{"key":"10.1016\/j.addr.2018.06.004_bb0080","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1513\/pats.200710-160DR","article-title":"What differentiates normal lung repair and fibrosis? Inflammation, resolution of repair, and fibrosis","volume":"5","author":"Strieter","year":"2008","journal-title":"Proc. Am. Thorac. Soc."},{"key":"10.1016\/j.addr.2018.06.004_bb0085","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1378\/chest.09-0510","article-title":"New mechanisms of pulmonary fibrosis","volume":"136","author":"Strieter","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.addr.2018.06.004_bb0090","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/modpathol.2013.198","article-title":"Idiopathic pulmonary fibrosis is strongly associated with productive infection by herpesvirus saimiri","volume":"27","author":"Folcik","year":"2014","journal-title":"Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc."},{"key":"10.1016\/j.addr.2018.06.004_bb0095","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/nature06244","article-title":"The human microbiome project","volume":"449","author":"Turnbaugh","year":"2007","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.addr.2018.06.004_bb0100","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00008-2017","article-title":"Lung microbiome and host immune tone in subjects with idiopathic pulmonary fibrosis treated with inhaled interferon-\u03b3","volume":"3","author":"Wang","year":"2017","journal-title":"ERJ Open Research"},{"issue":"7","key":"10.1016\/j.addr.2018.06.004_bb0105","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2213-2600(14)70088-8","article-title":"Respiratory microbiome in IPF: cause, effect, or biomarker?","volume":"2","author":"Molyneaux","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.addr.2018.06.004_bb0110","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/17826","article-title":"Inhibition of transforming growth factor-beta\/SMAD signalling by the interferon-gamma\/STAT pathway","volume":"397","author":"Ulloa","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.addr.2018.06.004_bb0115","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJM199910213411703","article-title":"A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis","volume":"341","author":"Ziesche","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2018.06.004_bb0120","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(09)60551-1","article-title":"Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial","volume":"374","author":"King","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2018.06.004_bb0125","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1128\/IAI.72.3.1275-1283.2004","article-title":"Aerosolized gamma interferon (IFN-gamma) induces expression of the genes encoding the IFN-gamma-inducible 10-kilodalton protein but not inducible nitric oxide synthase in the lung during tuberculosis","volume":"72","author":"Raju","year":"2004","journal-title":"Infect. Immun."},{"key":"10.1016\/j.addr.2018.06.004_bb0130","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1164\/rccm.200312-1670OC","article-title":"Effects of interferon-gamma 1b on biomarker expression in patients with idiopathic pulmonary fibrosis","volume":"170","author":"Strieter","year":"2004","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2018.06.004_bb0135","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1172\/JCI115291","article-title":"Organ specific cytokine therapy. Local activation of mononuclear phagocytes by delivery of an aerosol of recombinant interferon-gamma to the human lung","volume":"88","author":"Jaffe","year":"1991","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2018.06.004_bb0140","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1152\/jappl.1987.62.4.1603","article-title":"Human variation in the peripheral air-space deposition of inhaled particles","volume":"62","author":"Bennett","year":"1987","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.addr.2018.06.004_bb0145","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1089\/jam.2000.13.387","article-title":"Physiological and pathological considerations for aerosol deposition: expiration and models of deposition","volume":"13","author":"Smaldone","year":"2000","journal-title":"J. Aerosol Med."},{"issue":"Suppl 1","key":"10.1016\/j.addr.2018.06.004_bb0150","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1089\/jamp.2009.0786","article-title":"Mode of breathing-tidal or slow and deep-through the I-neb adaptive aerosol delivery (AAD) system affects lung deposition of (99m)Tc-DTPA","volume":"23","author":"Nikander","year":"2010","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2018.06.004_bb0155","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1089\/089426803769017640","article-title":"Parents' adherence with nebulizer treatment of their children when using an adaptive aerosol delivery (AAD) system","volume":"16","author":"Nikander","year":"2003","journal-title":"Journal of Aerosol Medicine: The Official Journal of the International Society for Aerosols in Medicine"},{"key":"10.1016\/j.addr.2018.06.004_bb0160","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1089\/jamp.2010.0817","article-title":"Omron NE U22: Comparison between vibrating mesh and jet nebulizer","volume":"23","author":"Skaria","year":"2010","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2018.06.004_bb0165","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1164\/ajrccm\/143.4_Pt_1.727","article-title":"Factors determining pulmonary deposition of aerosolized pentamidine in patients with human immunodeficiency virus infection","volume":"143","author":"Smaldone","year":"1991","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.addr.2018.06.004_bb0170","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/jamp.2011.0919","article-title":"Delivery and safety of inhaled interferon-gamma in idiopathic pulmonary fibrosis","volume":"25","author":"Diaz","year":"2012","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2018.06.004_bb0175","first-page":"37","article-title":"Inhaled interferon and diffusion capacity in idiopathic pulmonary fibrosis (IPF)","volume":"32","author":"Skaria","year":"2015","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"10.1016\/j.addr.2018.06.004_bb0180","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1164\/rccm.201006-0894CI","article-title":"Clinical course and prediction of survival in idiopathic pulmonary fibrosis","volume":"183","author":"Ley","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2018.06.004_bb0185","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1056\/NEJMra0804752","article-title":"Immunologic aspects of chronic obstructive pulmonary disease","volume":"360","author":"Cosio","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2018.06.004_bb0190","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0140-6736(04)15650-X","article-title":"Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase","volume":"363","author":"Barnes","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2018.06.004_bb0195","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1378\/chest.08-1385","article-title":"Emerging pharmacotherapies for COPD","volume":"134","author":"Barnes","year":"2008","journal-title":"Chest"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X18301418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X18301418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,5]],"date-time":"2018-11-05T09:20:27Z","timestamp":1541409627000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X18301418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":39,"alternative-id":["S0169409X18301418"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2018.06.004","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing of gamma interferon via inhalation delivery","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2018.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}